First-line diabetes therapies, DIY artificial pancreas use policies

[ad_1]

December 08, 2021

1 min read


We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Data has indicated thiazolidinedione pioglitazone and GLP-1 receptor agonists improve beta-cell function in patients with diabetes, prompting a meeting presenter to suggest both drugs be used as first-line therapies for the disease.

A discussion that covered both these topics was the top story in endocrinology last week.


Diabetes Words 2019

Photo source: Adobe stock.

Another top story provided new data on some of the possible downstream effects that patients with diabetes and a history of foot ulcer may experience, while another top story discussed some policy considerations for DIY artificial pancreases.

Read these and more top stories in endocrinology below:

Two diabetes drug classes can increase, maintain beta-cell function

The thiazolidinedione pioglitazone and GLP-1 receptor agonists are the only two diabetes drugs proved to increase and maintain beta-cell function, and both should be first-line therapies for patients, according to a speaker. Read more.

‘Death is a greater risk’ than amputation after diabetic foot ulcer

People with diabetes and a history of foot ulcer are more likely to die than undergo amputation during 6 years of follow-up, a potential measure of effectiveness of diabetes care, registry data from Scotland show. Read more.

Consensus group: Providers, policies must support DIY artificial pancreas use

Health care providers should facilitate and support people with diabetes who choose to use a do-it-yourself automated insulin delivery system, working together with patients to set “realistic” goals and minimize any hypoglycemia risk, the authors of a consensus statement wrote. Read more.

Data show race difference in relationship between glucose management indicator, HbA1c

Continuous glucose monitor data show a greater difference between HbA1c and the glucose management indicator metric for “non-white” vs. white adults with insulin-treated diabetes, which was also associated with higher risk for hypoglycemia. Read more.

Gastric bypass, sleeve gastrectomy ‘substantially’ reduce liver fat in type 2 diabetes

Roux-en-Y gastric bypass and sleeve gastrectomy are equally effective at reducing hepatic steatosis, with an almost complete clearance of liver fat 1 year after the surgical procedures, according to data from a single-center study. Read more.

[ad_2]

Source link